These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19097756)

  • 1. Fosfomycin in paediatric cancer patients: a feasible alternative to glycopeptides?
    Hepping N; Simon A
    Int J Antimicrob Agents; 2009 Apr; 33(4):389. PubMed ID: 19097756
    [No Abstract]   [Full Text] [Related]  

  • 2. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.
    Simon A; Gröger N; Wilkesmann A; Hasan C; Wiszniewsky G; Engelhart S; Kramer MH; Bode U; Ammann RA; Fleischhack G
    Int J Antimicrob Agents; 2006 Nov; 28(5):417-22. PubMed ID: 17046210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
    Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
    [No Abstract]   [Full Text] [Related]  

  • 4. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
    Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
    [No Abstract]   [Full Text] [Related]  

  • 5. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of fever in patients with cancer and treatment-induced neutropenia.
    Pizzo PA
    N Engl J Med; 1993 May; 328(18):1323-32. PubMed ID: 8469254
    [No Abstract]   [Full Text] [Related]  

  • 7. [Study and use of fosfomycin in the clinical field].
    Azzaroli P; de Martinis E; Zoli F; Garoia C
    G Ital Chemioter; 1978; 25(1):1-4. PubMed ID: 376386
    [No Abstract]   [Full Text] [Related]  

  • 8. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
    Bodey GP
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of fosfomycin in antibiotic therapy. Its effectiveness in patients with acute renal insufficiency or on hemodialysis treatment].
    Rossi R; Colantonio G; Fraticelli M; Giura C; Quarenghi MI; Polli O; Ferradini MA; Nonini MO
    G Ital Chemioter; 1979; 26(1-2):315-7. PubMed ID: 554823
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical experiments in the use of fosfomycin in oral microbial infections].
    Quaranta M
    Dent Cadmos; 1983 Mar; 51(3):57-64. PubMed ID: 6576933
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fosfomycin in severe infection in neonatology].
    Rossignol S; Regnier C
    Ann Pediatr (Paris); 1984 May; 31(5):437-44. PubMed ID: 6742722
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of cofosfolactamine in localized bacterial infections].
    Scalzini A; Chiodera A; Sueri L
    G Ital Chemioter; 1984; 31(1-2):205-6. PubMed ID: 6468828
    [No Abstract]   [Full Text] [Related]  

  • 13. [Phosphomycin for the prevention of bacterial infections in high risk patients].
    Faedda R; Tocco A; Vacca R; Deplano A; Olmeo NA; Branca FG; Bartoli E
    Clin Ter; 1981 Nov; 99(3):295-304. PubMed ID: 7307457
    [No Abstract]   [Full Text] [Related]  

  • 14. [Nephrological experiences in the treatment of urinary infections by fosfomycin].
    Mioli V; Figus S
    Minerva Med; 1978 Dec; 69(59):4093-6. PubMed ID: 740305
    [No Abstract]   [Full Text] [Related]  

  • 15. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
    Pizzo PA
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fosfomycin in urogenital infections. Experimental assumptions and clinical results].
    Savoia D; Fontana G; Laudi M; Cauda F
    Minerva Med; 1978 Dec; 69(59):4087-91. PubMed ID: 740304
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recommendations for the indication-justified use of antibiotics. 3: macrolides, lincosamide, glycopeptide antibiotics, fusidic acid, fosfomycin].
    Halle E; Briedigkeit H
    Z Arztl Fortbild (Jena); 1991 Dec; 85(24):1197-9. PubMed ID: 1776300
    [No Abstract]   [Full Text] [Related]  

  • 18. [Fosfomycin. II. Antimicrobial activity in vivo].
    Carlone NA; Cuffini AM; Savoia D
    G Batteriol Virol Immunol; 1977; 70(7-12):215-25. PubMed ID: 615746
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of the febrile patient with cancer and neutropenia.
    Buchanan GR
    J Pediatr; 1992 Apr; 120(4 Pt 1):669-70. PubMed ID: 1552422
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fosfomycin in a hematology department].
    Dinelli CA; Montrasio PL; Tansini G
    Minerva Med; 1978 Dec; 69(59):4111-4. PubMed ID: 740308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.